PDF(995 KB)
Cost-utility analysis of serplulimab combined with chemotherapy in the first-line treatment of PD-L1 （CPS≥1） locally advanced or metastatic esophageal squamous cell carcinoma
ZHAO Yingying, JU Wenxiang, ZHANG Xiaohan, LU Luolan, SHEN Aizong
Chinese Journal of Hospital Pharmacy ›› 2024, Vol. 44 ›› Issue (3) : 298-304.
PDF(995 KB)
PDF(995 KB)
Cost-utility analysis of serplulimab combined with chemotherapy in the first-line treatment of PD-L1 （CPS≥1） locally advanced or metastatic esophageal squamous cell carcinoma
({{custom_author.role_en}}), {{javascript:window.custom_author_en_index++;}}| {{custom_ref.label}} |
{{custom_citation.content}}
{{custom_citation.annotation}}
|
/
| 〈 |
|
〉 |
